Redhill Biopharma Ltd (RDHL.OQ) Quote| Reuters.com
Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

10.08USD
27 Jun 2016
Change (% chg)

-- (--)
Prev Close
$10.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,462
52-wk High
$19.00
52-wk Low
$8.10

RDHL.OQ

Chart for RDHL.OQ

About

RedHill Biopharma Ltd. is a biopharmaceutical company primarily focused on the development of late clinical-stage, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The Company’s pipeline of products includes RHB-105, RHB-104, BEKINDA... (more)

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -- -- --
ROI: -- -5.72 14.23
ROE: -- -4.83 15.46

BRIEF-Redhill Biopharma announces positive final results with endpoints in phase 1 study with Yeliva

* Redhill Biopharma announces positive final results with primary and secondary endpoints met in phase 1 study with Yeliva in advanced solid tumors

Jun 21 2016

BRIEF-Redhill Biopharma says Yeliva met main goal in early-stage study in solid tumors

* Redhill biopharma announces positive final results with primary and secondary endpoints met in phase 1 study with yeliva in advanced solid tumors

Jun 21 2016

BRIEF-Redhill Biopharma received $1.8 mln grant from U.S. National Cancer Institute for Yeliva phase II study

* Redhill biopharma announces National Cancer Institute grant supporting Yeliva phase II hepatocellular carcinoma study

May 05 2016

BRIEF-Redhill Biopharma reports Q1 loss per share $0.04

* Redhill biopharma reports 2016 first quarter financial results

Apr 20 2016

BRIEF-Redhill Biopharma initiates Phase II study of BEKINDA for irritable bowel syndrome

* Initiates Phase II study of BEKINDA for irritable bowel syndrome Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Apr 12 2016

BRIEF-Redhill biopharma provides interim results from phase IIa study supporting therapeutic potential of RHB-104 in multiple sclerosis

* Interim results from phase IIa proof-of-concept study supporting therapeutic potential of RHB-104 in multiple sclerosis

Mar 31 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.